Development research on immuno-gene therapy for malignant B-cell lymphoma

对于难治性恶性b细胞淋巴瘤（b细胞非霍奇金淋巴瘤）的治疗，我们进行了实验，开发了一种过继免疫基因疗法，使用表达靶向CD19的CAR（嵌合抗原受体）t细胞。我们证明了基因工程t细胞在体外和小鼠异种移植模型中有效地溶解cd19阳性b细胞淋巴瘤。这些结果表明，功能性工程t细胞将有效治疗难治性b细胞非霍奇金淋巴瘤。

For the treatment of refractory malignant B-cell lymphoma(B-cell non-Hodgkin lymphoma), we conducted experiments to develop an adoptive immuno-gene therapy using T-cells expressing a CAR(chimeric antigen receptor) targeting CD19.We demonstrated that genetically engineered T-cells efficiently lyzed CD19-positive B-cell lymphoma in vitro and in a mouse xenograft model. These results indicate that functional engineered T-cells would be effective for the treatment of refractory B-cell non-Hodgkin lymphoma.